Business Trends– category –
-
CCRM, OmniaBio, and Avectas Collaborate to Automate and Scale Cell Therapy Manufacturing
PR Newswire Canada Overview CCRM and its CDMO subsidiary OmniaBio Inc. have partnered with Avectas Limited to evaluate and integrate Avectas' automated, scalable cell therapy manufacturing platform. This collaboration aims to enhance con... -
Top Cell Therapy Startups Secure Significant Funding for Commercialization, Infrastructure, and Novel Modalities
New Market Pitch USA Overview Leading cell therapy startups are attracting substantial investment, indicating investor confidence in high-risk technical innovation. Companies like Orca (near-commercial assets), Cellares (manufacturing in... -
iPS-Derived Dopaminergic Neuron Transplants Show Early Safety and Efficacy, Offering New Hope for Parkinson’s Disease Treatment
NeurologyLive USA Overview Stem cell therapy involving the transplantation of iPS cell-derived dopaminergic neurons into the brain is emerging as a promising approach for Parkinson's disease (PD) treatment. Initial clinical trial results... -
Minaris Strengthens Philadelphia GMP Facility, Integrating Cell & Gene Therapy Manufacturing and Testing to Streamline Production
BriefGlance.com USA Overview Minaris, a leading CDMO, has significantly upgraded its GMP cell banking suite at its Philadelphia facility, aiming to streamline cell and gene therapy production. This expansion integrates manufacturing and ... -
Intellia Therapeutics Reports “Paradigm-Shifting” Phase 3 Data for Lonvoguran Ziclumeran, Achieving 87% Reduction in HAE Attacks with Single In Vivo CRISPR Dose
Fierce Biotech USA Overview Intellia Therapeutics announced groundbreaking Phase 3 HAELO trial data for lonvoguran ziclumeran (lonvo-z), an *in vivo* CRISPR gene-editing therapy for hereditary angioedema (HAE). This one-time treatment de... -
Beam Therapeutics Receives FDA IND Clearance for BEAM-304, Advancing Base Editing Therapy for Phenylketonuria (PKU) into Clinical Development
GlobeNewswire USA Overview Beam Therapeutics Inc. announced that the FDA has cleared its Investigational New Drug (IND) application for BEAM-304, a base editing therapy for Phenylketonuria (PKU). PKU is a rare genetic metabolic disorder ... -
Jazz Pharmaceuticals and AbCellera Partner for Next-Gen Multispecific T-Cell Engagers Targeting GI and Solid Tumors, with Up to $848M in Potential Payments
PR Newswire USA Overview Jazz Pharmaceuticals and AbCellera have entered a research collaboration, option, and license agreement to discover and develop next-generation multispecific T-cell engager antibodies for gastrointestinal cancers... -
Autolus Therapeutics Wins Prix Galien UK for Best Biotech Product, Reports Promising Early Phase 1 Data for obe-cel CAR-T in Refractory SLE
Stock Titan UK Overview Autolus Therapeutics plc received the 2026 Prix Galien UK Award for Best Biotechnology Product, recognizing its pioneering work in next-generation T-cell therapies developed with University College London. Concurr... -
Editas Medicine Unveils Positive Preclinical Data for Gene Editing Candidate EDIT-401, Demonstrating Significant Reduction in LDL, Lp(a), and ApoB in Non-Human Primates
Investing.com USA Overview Editas Medicine announced positive preclinical data for its gene editing therapeutic candidate EDIT-401, showing significant reductions in LDL cholesterol, lipoprotein(a) (Lp(a)), and apolipoprotein B (ApoB) in... -
Intellia’s Lonvo-z Achieves 87% Reduction in HAE Attack Rate and 62% Attack-Free Patients in Pivotal Phase 3 In Vivo CRISPR Trial
GlobeNewswire USA Overview Intellia Therapeutics has reported highly positive Phase 3 HAELO clinical trial results for lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene editing therapy for hereditary angioedema (HAE). The therapy a...
